Walter Mazzei, MD
Clinical Cardiac Electrophysiology · Columbia, SCNPI 1083948285
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,625 of the $96,397 with a category attached, or 88.8%. Boston Scientific accounts for 90.9% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $87,618, more than ten times the $1,312 reported in 2019.
Across 531 payments — averaging $181.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$88K
- Medtronic$5K
- Biosense Webster, Inc.$1K
- Novartis$430
- Pfizer$313
- Philips North America LLC$293
- plus $1K from 19 others
Across 10 payments — averaging $15,774 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$158K
What the payments were for
- Speaking & faculty fees$85,62589%
- Food & beverage$10,77211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 137 | $87,623 |
| Medtronic(2 entities) | 234 | $5,134 |
| Biosense Webster, Inc. | 31 | $1,255 |
| Novartis | 29 | $430 |
| Pfizer | 15 | $313 |
| Philips North America LLC | 11 | $293 |
| E.r. Squibb & Sons, L.L.C. | 14 | $241 |
| Atricure, Inc. | 10 | $234 |
| Cardiva Medical, Inc. | 17 | $234 |
| Amgen | 10 | $146 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $146 |
| Johnson & Johnson | 4 | $59 |
| Boehringer Ingelheim | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Cvrx, Inc. | 1 | $30 |
| Abbott | 1 | $29 |
| Recor Medical Inc | 1 | $26 |
| Novo Nordisk | 1 | $22 |
| Bayer | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Terumo Medical Corporation | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL EP$85,625
- Micra$682
- Reveal LINQ$585
- Carto 3$544
- Arctic Front$425
- Watchman$366
- AZURE XT DR MRI SURESCAN$298
- LINQ II$291
- WATCHMAN Access System$250
- Carto 3 System$216
- ARCTIC FRONT ADVANCE$190
- CardioInsight$167
- OMNIASECURE MRI SURESCAN$156
- Advisa$155
- Farapulse$140
- Rhythmia Mapping System$119
- Cobalt$114
How this compares
$96,397 in reported general payments places this provider in the 80th percentile of 58 clinical cardiac electrophysiology providers in South Carolina.
See all clinical cardiac electrophysiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 373 | $421,479 |
| XareltoRivaroxaban | 102 | $94,960 |
| Dofetilide | 55 | $9,397 |
| Flecainide Acetate | 105 | $5,597 |
| SotalolSotalol Hcl | 114 | $3,368 |
| Metoprolol Succinate | 162 | $3,152 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 55 | $2,296 |
| Metoprolol Tartrate | 96 | $1,223 |
| Warfarin Sodium | 65 | $1,190 |
| Amiodarone Hcl | 70 | $903 |
| Atorvastatin Calcium | 66 | $805 |
| Losartan Potassium | 46 | $758 |
| ClopidogrelClopidogrel Bisulfate | 53 | $650 |
| Carvedilol | 51 | $596 |
| Lisinopril | 44 | $476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $313 | $421,479373 claims |
| Johnson & JohnsonXarelto | $59 | $94,960102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 58 clinical cardiac electrophysiology providers in South Carolina.
Other clinical cardiac electrophysiology in Columbia
- Sultan SiddiqueColumbia$182K
- Todd SennColumbia$49K
- Venkateshwar GottipatyColumbia$46K
- Francis UgoweColumbia$43K
- Jennifer FeldmanColumbia$19K
- Paras PatelColumbia$10K
- Gerald BauknightColumbia$10K
- Donald SiddowayColumbia$8K
- Hampton CollinsColumbia$22
- Jeffrey WinterfieldCharleston$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.